BACTERIOSTATIC WATER FOR INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Bacteriostatic Water for Injection Market Size and Trends

Global bacteriostatic water for injection market is estimated to be valued at USD 1.22 Billion in 2024 and is expected to reach USD 2.09 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 8% from 2024 to 2031. Global bacteriostatic water for injection growth is driven by factors like rising prevalence of chronic diseases and increasing number of surgeries being performed.

To learn more about this report, Request sample copy

Market Driver - Increasing demand for injectable drugs

Rising demand for injectable drugs due to their rapid absorption and onset of action can drive the market growth. Administering drugs intravenously allows for direct introduction into the bloodstream, thus, bypassing the hepatic first-pass metabolic process that helps in attaining higher bioavailability.

Rising one-time dosage medications, which are very convenient for patients opposed to oral treatments requiring multiple daily pills, also boosts preference for injectable drugs. Self-injectable devices have become very sophisticated, thus, allowing for convenient home administration without requiring frequent hospital or clinic visits. This has especially benefited chronic disease patients in need of long-term management. Geriatric population prone to various co-morbidities boosts demand for injectable drugs to counter poor absorption related to aging physiology and difficulties in swallowing large oral pills.

Increasing complexity of drug molecules and monoclonal antibodies has raised safety concerns about toxic contaminants if administered orally. Sterile packaging and filling of injectable drugs ensures exclusion of pyrogens, microbial contaminants and other impurities. This makes injections the only viable option for these advanced medications, which are being developed intensively for severe diseases. The injectable route of delivery also allows inclusion of controlled release formulations through depot injections to achieve steadier drug levels over weeks or months with less frequent dosing. For instance, in May 2022, the U.S. Food and Drug Administration granted approval to Eli Lilly for Mounjaro (tirzepatide) injection, a novel once-weekly treatment that functions as a GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This medication is designed to enhance glycemic control in adults diagnosed with type 2 diabetes.

To learn more about this report, Request sample copy

Growth of biopharmaceuticals

Growing biopharmaceuticals industry can drive the market growth. Continuous focus on research and development of sophisticated biologic entities to target complex disease pathways has resulted in approval and launch of novel biologics. Engineered for high specificity and efficacy, these biologic drugs have transformed treatment landscapes but includes high costs of development and manufacturing challenges. Most approved biologic drugs require intravenous or subcutaneous injection, owing to their large molecular structure and sensitivity to GI conditions if orally administered.

Constant advancements are being made to produce next-generation monoclonal antibodies, fusion proteins, vaccines and gene and cell therapies. Their production involves fermentation and purification in closed sterile environments. After initial studies confirm safety and efficacy, scaling up of manufacturing becomes crucial to meet growing demands. This involves bulk sterile filling of biologic drug products into vials, prefilled syringes or cartridges from which final dosage forms are prepared for parenteral administration. Bacteriostatic water acts as a sterile solvent used widely during the steps of dissolving, diluting or reconstituting lyophilized biopharmaceutical drug powders post manufacturing.

Rising investments from large pharmaceutical companies as well as smaller biotech startups can lead to increase in number of biologic drugs in clinical pipelines and undergoing FDA/EMA review. With successful approvals, these candidate molecules will require commercial scale sterile filling into final containers from where these will be dispensed for hospital and clinical use. Expanding market landscape of sophisticated biologic therapies can boost demand for bacteriostatic water used during their preparation, handling and administration processes.